Microcap Ledger

Tickers · $NEPH

Nephros Inc $NEPH

By Microcap Ledger desk · CIK 0001196298

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Surgical & Medical Instruments & Apparatus
Headquarters
South Orange, NJ
Fiscal year end
December 31
Shares outstanding
10,860,120 [10-Q 2026-08-10]
as of 2026-08-07

Sources: [10-K 2026-03-12]

What the company doesAI summary of filing

Nephros is a commercial-stage company that develops and markets point-of-use water filtration products for medical and commercial applications. The company's medical portfolio includes FDA 510(k)-cleared Class II ultrafilters and microfilters for infection control and dialysis water purification in healthcare settings, while its commercial product line addresses water quality concerns in foodservice, hospitality, and other industries through carbon-based and carbon-free filtration solutions. Nephros does not manufacture its medical devices but contracts with Medica, an Italy-based manufacturer, under an exclusive supply agreement, while manufacturing some commercial products in-house at its South Orange, New Jersey facility. The company generates revenue through direct sales and distributor relationships serving hospitals, dialysis clinics, foodservice operations, and other commercial and industrial customers. [10-K 2026-03-12]

Segments: Infection Control (medical ultrafiltration and microfiltration), Dialysis Water (medical ultrafiltration), Commercial Water Filtration (carbon-based and carbon-free solutions)

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$11.23M$1.34M −$990.0K$4.70M[10-Q 2026-08-10]
FY ended Dec 2025$18.79M$1.19M $1.60M$5.40M[10-K 2026-03-12]
FY ended Dec 2024$14.16M$74.0K −$492.0K$3.76M[10-K 2026-03-12]
Quarterly cash burn
−$495.0K
Cash runway Estimate
~28.5 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-0410,544,225[10-Q 2024-11-14]
2025-03-1710,600,350[10-K 2025-03-24]
2025-05-0610,600,350[10-Q 2025-05-15]
2025-08-0710,600,604[10-Q 2025-08-07]
2025-11-0310,626,683[10-Q 2025-11-06]
2026-03-1210,644,268[10-K/A 2026-04-30]
2026-05-0410,856,546[10-Q 2026-05-07]
2026-08-0710,860,120[10-Q 2026-08-10]
Shelf registration
S-3 filed 2024-05-10; declared effective 2024-05-23 [S-3 2024-05-10]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-09-14Wexford Capital Lpother3,355,111—[4 2026-09-16]
2026-09-14Wexford Capital Lpother22,710$3.95[4 2026-09-16]
2026-09-14Amron Arthur Hother17,749—[4 2026-09-16]
2026-09-14Amron Arthur Hother2,836—[4 2026-09-16]
2026-09-14Amron Arthur Hother22,710$3.95[4 2026-09-16]
2026-08-18Wexford Capital Lpexercise812$3.60[4 2026-08-20]
2026-08-12Amron Arthur Hgrant2,418—[4 2026-08-14]
2026-05-11Amron Arthur Hgrant3,574—[4 2026-06-12]
2026-03-23Banks Robert R. Jr.exercise120,000$1.44[4 2026-03-25]
2026-03-23Krandel Judyexercise68,861$1.71[4 2026-03-25]
2026-03-16Amron Arthur Hgrant3,610—[4 2026-03-18]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.